Shire PLC Company Profile (NASDAQ:SHPG)

Shire PLC trades on the NASDAQ under the ticker symbol "SHPG."

Shire PLC announced a dividend on Friday, February 24th. Shareholders of record on Friday, March 10th will be paid a dividend of $0.771 per share on Tuesday, April 25th. The ex-dividend date of this dividend is Wednesday, March 8th. This is a boost from Shire PLC's previous dividend of $0.14. View Shire PLC's Dividend History.

Shire PLC (NASDAQ:SHPG) issued its quarterly earnings data on Tuesday, May, 2nd. The company reported $3.63 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $3.22 by $0.41. The business had revenue of $3.57 billion for the quarter. Shire PLC had a net margin of 2.14% and a return on equity of 13.05%. The business's revenue was up 109.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.12 earnings per share. View Shire PLC's Earnings History.

Shire PLC issued an update on its FY17 earnings guidance on Tuesday, May, 2nd. The company provided earnings per share guidance of $14.60-15.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.00. The company issued revenue guidance of $14.5-14.8 billion, compared to the consensus revenue estimate of $15.23 billion.

20 equities research analysts have issued 12-month price objectives for Shire PLC's stock. Their predictions range from $198.00 to $325.00. On average, they anticipate Shire PLC's share price to reach $229.10 in the next year. View Analyst Ratings for Shire PLC.

Here are some recent quotes from research analysts about Shire PLC stock:

• 1. According to Zacks Investment Research, "The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology space, acquiring roughly 22% of the total market by the end of Mar 2017. The Dyax acquisition has integrated well and Shire announced positive results from the phase III trial on lanadelumab in May 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Earnings estimates have fallen lately ahead of the Q2 results. Shire has a positive record of earnings surprises in the recent quarters." (7/17/2017)
• 2. Jefferies Group LLC analysts commented, "SHPG posted strong 4Q16 revs ($3.8B vs $3.7B JEF) and EPS ($3.37 vs $3.26 JEF) as nearly all core franchises performed well. In particular, GI and Orphan Diseases showed strength. As for legacy BXLT, Immunoglobulins and Hemophilia performed well while Inhibitors lagged. We like the setup for 2017. If mgt executes on core brands, the Xiidra launch, and the BXLT integration, we could envision share price outperformance, augmented by significant deleveraging." (2/17/2017)

Shire PLC saw a increase in short interest in the month of July. As of July 14th, there was short interest totalling 1,247,044 shares, an increase of 34.9% from the June 30th total of 924,373 shares. Based on an average trading volume of 1,330,164 shares, the days-to-cover ratio is currently 0.9 days.

Some companies that are related to Shire PLC include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis AG (NVS), Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Company (BMY), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX) and Patheon NV (PTHN).

Shire PLC's management team includes the folowing people:

• Flemming Ornskov M.D., Chief Executive Officer, Executive Director
• Jeffrey Poulton, Chief Financial Officer, Executive Director
• William Mordan, General Counsel, Company Secretary
• Perry Sternberg, Head - U.S. Commercial
• Kim Stratton, Head - International Commercial
• Philip J. Vickers, Head - Research and Development
• Matthew Walker, Head - Technical Operations
• Susan Saltzbart Kilsby, Independent Non-Executive Chairman of the Board
• Olivier Bohuon, Non-Executive Director
• Ian T. Clark, Non-Executive Director

Shire PLC's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Rockefeller Financial Services Inc. (0.00%), Selz Capital LLC (0.03%), Aperio Group LLC (0.00%), Fisher Asset Management LLC (0.00%), Gateway Investment Advisers LLC (0.00%) and US Bancorp DE (0.00%). View Institutional Ownership Trends for Shire PLC.

Shire PLC's stock was sold by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Rockefeller Financial Services Inc., Quantitative Systematic Strategies LLC, Bank of Montreal Can, Catawba Capital Management VA, Leavell Investment Management Inc., Private Trust Co. NA and Fox Run Management L.L.C.. View Insider Buying and Selling for Shire PLC.

Shire PLC's stock was purchased by a variety of institutional investors in the last quarter, including Selz Capital LLC, Gateway Investment Advisers LLC, Osborne Partners Capital Management LLC, US Bancorp DE, Heritage Investors Management Corp, Breton Hill Capital Ltd., Altfest L J & Co. Inc. and Addison Capital Co. View Insider Buying and Selling for Shire PLC.

Shares of Shire PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Shire PLC stock can currently be purchased for approximately $166.11.